GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Purchase Of Investment

PULM (Pulmatrix) Purchase Of Investment : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pulmatrix Purchase Of Investment?

Pulmatrix's purchase of investment for the three months ended in Sep. 2024 was $0.00 Mil. It means Pulmatrix spent $0.00 Mil on purchasing investments. Pulmatrix's purchase of investment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), Pulmatrix spent the same money on purchasing investments in Sep. 2024 ($0.00 Mil).

Pulmatrix Purchase Of Investment Historical Data

The historical data trend for Pulmatrix's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Purchase Of Investment Chart

Pulmatrix Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pulmatrix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pulmatrix Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmatrix Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Pulmatrix's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmatrix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Purchase Of Investment
Comparable Companies
HOOK GOVX AEON NXTC INKT IBIO EQ KAPA NKGN NNVC VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
2PU:Germany
Address
36 Crosby Drive, Suite 100, Bedford, MA, USA, 01730
Website
https://www.pulmatrix.com
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Executives
Peter Ludlum officer: Interim CFO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski officer: Chief Medical Officer C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan director C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore director C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert officer: Vice President, Finance 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen other: Former 10% owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint 10 percent owner 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210